Evidence map›Paper›PMID 28283904›Full record

ArticleBreast cancer research and treatment2017

Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).

Gretchen G Kimmick, Brittny Major, Jonathan Clapp, Jeff Sloan, Brandelyn Pitcher, Karla Ballman, Myra Barginear, Rachel A Freedman, Andrew Artz, Heidi D Klepin and 9 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00068328 (Observational Cohort Study), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00068328 completednot on this map

Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer

TypeobservationalSponsorAlliance for Clinical Trials in OncologyRan2003 to 2016Enrolled1,706ConditionsBreast Cancer, Psychosocial Effects of Cancer and Its TreatmentArmspsychosocial assessment and care, quality-of-life assessment
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Use of Surveillance Mammography Among Older Breast Cancer Survivors by Life Expectancy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gretchen G KimmickDuke Cancer Institute, Duke University Medical Center, Box 3204, Durham, NC, 29910, USA. gretchen.kimmick@duke.edu.ORCID http://orcid.org/0000-0001-7096-9624
Brittny MajorAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Jonathan ClappDepartment of Oncology, MedStar Georgetown University Medical Center, Washington, DC, USA.
Jeff SloanAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Brandelyn PitcherDuke Cancer Institute, Duke University Medical Center, Box 3204, Durham, NC, 29910, USA.
Karla BallmanDivision of Biostatistics and Epidemiology, Weill Medical College of Cornell University, New York, NY, USA.
Myra BarginearHofstra-North Shore LIJ School of Medicine, Northwell Health Cancer Institute, Lake Success, NY, USA.
Rachel A FreedmanDana-Farber/Partners CancerCare, Boston, MA, USA.
Andrew ArtzUniversity of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
Heidi D KlepinWake Forest University School of Medicine, Winston-Salem, NC, USA.
Jacqueline M LafkyAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Judith HopkinsForsyth Regional Cancer Center, Winston-Salem, NC, USA.
Eric WinerDana-Farber/Partners CancerCare, Boston, MA, USA.
Clifford HudisAmerican Society of Clinical Oncology, Alexandria, VA, USA.
Hyman MussUNC Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Harvey CohenDuke Cancer Institute, Duke University Medical Center, Box 3204, Durham, NC, 29910, USA.
Aminah JatoiMayo Clinic, Rochester, MN, USA.
Arti HurriaCity of Hope, Duarte, CA, USA.
Jeanne MandelblattDepartment of Oncology and Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, MedStar Georgetown University Medical Center, Georgetown University, Washington, DC, USA.

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
CANCER AND LEUKEMIA GROUP B MINORITY SATELLITE SUPPLEMENU10CA031946 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 1985 to 2013
$158.4M
Collaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6M
CANCER &LEUKEMIA GROUP B STATISTICAL CENTERU10CA033601 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SARGENT, DANIEL J. · 1985 to 2013
$69.4M
The HMO Cancer Research Network (CRN)U19CA079689 · NCI · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI MAZOR, KATHLEEN MICHELE · 1999 to 2011
$62.6M
Training and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Bao Q Vuong · 2008 to 2026
$28.9M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADRIANA ESPINOSA, FRANCESCA M GANY · 2008 to 2026
$28.1M
Northwell Health NCORPUG1CA189850 · NCI · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI VINCENT P VINCIGUERRA · 2014 to 2026
$13.3M
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)UG1CA232760 · NCI · MAYO CLINIC ROCHESTER · PI Judy Caroline Boughey, Aaron Scott Mansfield · 2019 to 2026
$8.5M
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINER01CA129769 · NCI · GEORGETOWN UNIVERSITY · PI AHLES, TIM ALAN, MANDELBLATT, JEANNE · 2009 to 2020
$7.3M
NORTH SHORE UNIV COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA035279 · NCI · NORTH SHORE UNIVERSITY HOSPITAL · PI VINCIGUERRA, VINCENT P · 1985 to 2014
$7.3M
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic SiteU10CA180790 · NCI · MAYO CLINIC ROCHESTER · PI ALBERTS, STEVEN R, BOUGHEY, JUDY CAROLINE · 2014 to 2018
$6.6M
NCI NIH HHS K05 CA096940NCI NIH HHS R01 CA124924NCI NIH HHS R01 CA127617NCI NIH HHS R01 CA129769NCI NIH HHS R35 CA197289NCI NIH HHS U10 CA003927NCI NIH HHS U10 CA007968NCI NIH HHS U10 CA031946NCI NIH HHS U10 CA032291NCI NIH HHS U10 CA033601NCI NIH HHS U10 CA035279NCI NIH HHS U10 CA041287NCI NIH HHS U10 CA047559NCI NIH HHS U10 CA047577NCI NIH HHS U10 CA077597NCI NIH HHS U10 CA084131NCI NIH HHS U10 CA180790NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180836NCI NIH HHS U10 CA180838NCI NIH HHS U10 CA180857NCI NIH HHS U10 CA180867NCI NIH HHS U19 CA079689NCI NIH HHS U54 CA132378NCI NIH HHS U54 CA137788NCI NIH HHS UG1 CA189823NCI NIH HHS UG1 CA189850NCI NIH HHS UG1 CA232760
6 · The paper itself

Abstract

purposeTools to estimate survival, such as ePrognosis ( http://eprognosis.ucsf.edu/carey2.php ), were developed for general, not cancer, populations. In older patients with breast cancer, accurate overall survival estimates would facilitate discussions about adjuvant therapies.

methodsSecondary analyses were performed of data from two parallel breast cancer studies (CALGB/Alliance 49907/NCT000224102 and CALGB/Alliance 369901/NCT00068328). We included patients (n = 971) who were age 70 years and older with complete baseline quality of life data (194 from 49907; 777 from 369901). Estimated versus observed all-cause two-year mortality rates were compared. ePrognosis score was calculated based on age, sex, and daily function (derived from EORTC QLQ-C30). ePrognosis scores range from 0 to 10, with higher scores indicating worse prognosis based on mortality of community-dwelling elders and were categorized into three groups (0-2, 3-6, 7-10). Observed mortality rates were estimated using Kaplan-Meier methods.

resultsPatient mean age was 75.8 years (range 70-91) and 73% had stage I-IIA disease. Most patients were classified by ePrognosis as good prognosis (n = 562, 58% 0-2) and few (n = 18, 2% 7-10) poor prognosis. Two-year observed mortality rates were significantly lower than ePrognosis estimates for patients scoring 0-2 (2% vs 5%, p = 0.001) and 3-6 (8% vs 12%, p = 0.01). The same trend was seen with scores of 7-10 (23% vs 36%, p = 0.25).

conclusionsePrognosis tool only modestly overestimates mortality rate in older breast cancer patients enrolled in two cooperative group studies. This tool, which estimates non-cancer mortality risk based on readily available clinical information may inform adjuvant therapy decisions but should be validated in non-clinical trial populations.

Indexed as

AgedAged, 80 and overBreast NeoplasmsClinical Trials as TopicFemaleHumansKaplan-Meier EstimateLeukemiaPrognosisQuality of LifeBreast cancerElderlyePrognosisSurvival estimates

Identifiers

PMID28283904
PMCPMC5508575

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.